	US 12,064,509 B2
	Enema for rectal application
Yoji Yamada, Tokyo (JP); Syoji Kondo, Tokyo (JP); and Toshifumi Kajioka, Tokyo (JP)
Assigned to Dr. Falk Pharma Gmbh, Freiburg (DE)
Filed by Dr. Falk Pharma GmbH, Freiburg (DE)
Filed on Jan. 21, 2022, as Appl. No. 17/581,354.
Application 17/581,354 is a continuation of application No. 15/546,476, abandoned, previously published as PCT/JP2015/070667, filed on Jul. 21, 2015.
Prior Publication US 2022/0142921 A1, May 12, 2022
Int. Cl. A61K 9/12 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/58 (2006.01); A61P 1/00 (2006.01)

CPC A61K 9/12 (2013.01) [A61K 9/0031 (2013.01); A61K 9/08 (2013.01); A61K 31/58 (2013.01); A61P 1/00 (2018.01)]

8 Claims

1. A method of treating inflammatory bowel disease or preventing relapse of inflammatory bowel disease by transanally administering to a subject in need thereof an enema comprising 1.5 to 2.5 mg of budesonide twice a day for 6 weeks.